Effect of kava (Piper methysticum) on peripheral gene expression among individuals with generalized anxiety disorder: A post hoc analysis of a randomized controlled trial.

gene expression generalized anxiety disorder kava

Journal

Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486

Informations de publication

Date de publication:
Dec 2023
Historique:
revised: 23 06 2023
received: 20 12 2022
accepted: 17 08 2023
pubmed: 28 9 2023
medline: 28 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

Kava is a South Pacific plant-based medicine with anxiolytic properties, but little is known about the impact kava has on gene expression or whether gene expression can serve as a marker of kava response. This study aimed to determine whether kava treatment alters the expression of genes with physiological relevance to anxiety pathophysiology and whether the baseline expression of these physiologically relevant genes modifies the efficacy of kava treatment. In this post hoc analysis, we examined the expression of 48 genes relevant to the pathophysiology of anxiety collected from a double-blind randomized controlled trial that assessed the efficacy of kava treatment in generalized anxiety disorder. Peripheral blood gene expression was measured in 71 (34 kava, 37 placebo) adults at baseline and in 40 (19 kava, 21 placebo) after 8 weeks of treatment by reverse transcription polymerase chain reaction (PCR). Results revealed that kava decreased the expression of a subunit of the GABA

Identifiants

pubmed: 37767766
doi: 10.1002/ptr.7999
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5897-5903

Subventions

Organisme : National Health and Medical Research Council
ID : APP1063383
Organisme : Integria Healthcare
Organisme : NHMRC Clinical Research Fellowship
ID : APP1125000

Informations de copyright

© 2023 John Wiley & Sons Ltd.

Références

Chua, H. C., Christensen, E. T., Hoestgaard-Jensen, K., Hartiadi, L. Y., Ramzan, I., Jensen, A. A., Absalom, N. L., & Chebib, M. (2016). Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: Functional characteristics and molecular mechanism. PLoS One, 11(6), e0157700.
File, S. E., Kenny, P. J., & Cheeta, S. (2000). The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacology Biochemistry and Behavior, 66(1), 65-72.
Gordon, J. A., & Hen, R. (2004). The serotonergic system and anxiety. Neuromolecular Medicine, 5(1), 27-40.
Kalueff, A. V., & Nutt, D. J. (2007). Role of GABA in anxiety and depression. Depression and Anxiety, 24(7), 495-517.
McCall, M. N., McMurray, H. R., Land, H., & Almudevar, A. (2014). On non-detects in qPCR data. Bioinformatics, 30(16), 2310-2316.
Pittler, M. H., & Ernst, E. (2003). Kava extract versus placebo for treating anxiety. Cochrane Database of Systematic Reviews, 2003(1), CD003383. https://doi.org/10.1002/14651858.CD003383
Rex, A., Morgenstern, E., & Fink, H. (2002). Anxiolytic-like effects of kava-kava in the elevated plus maze test-A comparison with diazepam. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26(5), 855-860.
Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry, 63, 9-16.
Sarris, J., Byrne, G. J., Bousman, C. A., Cribb, L., Savage, K. M., Holmes, O., Murphy, J., Macdonald, P., Short, A., & Nazareth, S. (2020). Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Australian and New Zealand Journal of Psychiatry, 54(3), 288-297.
Sarris, J., LaPorte, E., & Schweitzer, I. (2011). Kava: A comprehensive review of efficacy, safety, and psychopharmacology. Australian and New Zealand Journal of Psychiatry, 45(1), 27-35.
Savage, K. M., Stough, C. K., Byrne, G. J., Scholey, A., Bousman, C., Murphy, J., Macdonald, P., Suo, C., Hughes, M., & Thomas, S. (2015). Kava for the treatment of generalised anxiety disorder (K-GAD): Study protocol for a randomised controlled trial. Trials, 16(1), 1-13.
Sullivan, P. F., Fan, C., & Perou, C. M. (2006). Evaluating the comparability of gene expression in blood and brain. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 141(3), 261-268.
van Buuren, S. V., & Groothuis-Oudshoorn, K. (2011). Mice: Multivariate imputation by chained equations in R. Journal of Statistical Software, 45(3), 1-67.

Auteurs

Lachlan Cribb (L)

Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia.

Jerome Sarris (J)

NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.

Karen M Savage (KM)

Department of Psychiatry, ACT Health, Canberra, Australia.

Gerard J Byrne (GJ)

Department of Psychiatry, ACT Health, Canberra, Australia.
School of Clinical Medicine, Discipline of Psychiatry, The University of Queensland, Queensland, Australia.

Najwa-Joelle Metri (NJ)

NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia.

Andrew Scholey (A)

Centre for Human Psychopharmacology, Hawthorn, Swinburne University of Technology, Victoria, Australia.

Con Stough (C)

Centre for Human Psychopharmacology, Hawthorn, Swinburne University of Technology, Victoria, Australia.

Chad A Bousman (CA)

Department of Medical Genetics, Psychiatry, Physiology & Pharmacology Calgary, Alberta, Canada.
Department of Psychiatry Parkville, Victoria, Australia.

Classifications MeSH